Prospective Randomized Controlled Study of Cardiopretective Effect of Dexrazoxane on the Female Breast Cancer Patients with Postoperative Chemotherapy
Xiao Xiang-sheng
Abstract
Xiao Xiang-sheng
Abstract
Objective To observe the protective effect of dexrazoxane on cardiotoxicity induced by epirubicin.Methods A total of 117 female patients with breast cancer were randomly assigned to be treated with anthracyclines,received anthracycline-based chemotherapy either with(n=61)or without(n=56) dexrazoxane for 6cycles.All of the patients were continuous follow-up in 2 years,monitoring the cardiac function condition before treatment,after treatment every cycle,complete,1 year after treatment,2 years after treatment by the myocardial calcium protein,myocardial enzymes,left ventricular ejection fraction.Results Compared with those receiving anthracycline alone,patients teated with dexrazoxane experienced significantly fewer cardiacevents and less heart toxicity.Conclusion Dexrazoxane not only has cardiao-protective activty against cardio-toxicity induced by epirubicin.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To observe the protective effect of dexrazoxane on cardiotoxicity induced by epirubicin.Methods A total of 117 female patients with breast cancer were randomly assigned to be treated with anthracyclines,received anthracycline-based chemotherapy either with(n=61)or without(n=56) dexrazoxane for 6cycles.All of the patients were continuous follow-up in 2 years,monitoring the cardiac function condition before treatment,after treatment every cycle,complete,1 year after treatment,2 years after treatment by the myocardial calcium protein,myocardial enzymes,left ventricular ejection fraction.Results Compared with those receiving anthracycline alone,patients teated with dexrazoxane experienced significantly fewer cardiacevents and less heart toxicity.Conclusion Dexrazoxane not only has cardiao-protective activty against cardio-toxicity induced by epirubicin.
Key concepts: Dexrazoxane, Epirubicin, Anthracycline, Medicine, Cardiotoxicity, Chemotherapy, Breast cancer, Internal medicine